The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.
Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.
Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
The diagnostics company said the number of tests accessioned during the quarter grew 60 percent year over year.
The test analyzes microRNA expression in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.